{"protocolSection": {"identificationModule": {"nctId": "NCT01590797", "orgStudyIdInfo": {"id": "0431-254"}, "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)", "officialTitle": "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy, Alone or in Combination With Metformin"}, "statusModule": {"statusVerifiedDate": "2018-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-07-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2014-06-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-06-25", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-05-01", "studyFirstSubmitQcDate": "2012-05-02", "studyFirstPostDateStruct": {"date": "2012-05-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-01-16", "resultsFirstSubmitQcDate": "2015-01-16", "resultsFirstPostDateStruct": {"date": "2015-01-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-07-20", "lastUpdatePostDateStruct": {"date": "2018-08-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable insulin alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis of this study is that after 24 weeks, the addition of sitagliptin compared with placebo provides greater reduction in hemoglobin A1C (HbA1C) in T2DM participants on insulin alone or in combination with metformin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 467, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.", "interventionNames": ["Drug: Sitagliptin", "Biological: Insulin", "Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants treated with placebo matching sitagliptin, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.", "interventionNames": ["Drug: Placebo", "Biological: Insulin", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin", "description": "Sitagliptin 100 mg once daily for 24 weeks", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia\u00ae", "MK-0431"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo once daily for 24 weeks", "armGroupLabels": ["Placebo"]}, {"type": "BIOLOGICAL", "name": "Insulin", "description": "Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.", "armGroupLabels": ["Placebo", "Sitagliptin"]}, {"type": "DRUG", "name": "Metformin", "description": "At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.", "armGroupLabels": ["Placebo", "Sitagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin", "timeFrame": "Baseline and Week 24"}, {"measure": "Number of Participants With One or More Adverse Events", "description": "An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to Week 26"}, {"measure": "Number of Participants Discontinuing Study Medication Due to an AE", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in HbA1C Levels at Week 24 in Participants Receiving Insulin in Combination With Metformin", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin", "timeFrame": "Baseline and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* has T2DM\n* is currently on a stable regimen of pre-mixed, intermediate-acting, or long-acting insulin at a dose of at least 12 U/day, either alone or in combination with metformin \\>=1500 mg/day for \u2265 10 weeks\n* has a Visit 1/Screening HbA1C between 7.5% and 11.0%\n* is a male, or a female who is highly unlikely to conceive during the study and for 14 days after the last dose of study medication\n\nExclusion Criteria:\n\n* has been treated with any antihyperglycemic therapies other than a protocol-required insulin (alone or with metformin) within the prior 12 weeks or has ever\n\nbeen treated with a dipeptidyl peptidase-4 inhibitor or a glucagon-like peptide-1 mimetic or analogue\n\n* is currently on treatment with daily use (one or more injections per day) of\n\npre-prandial short-acting or rapid-acting insulin\n\n* has a history of 2 or more episodes of hypoglycemia resulting in seizure,\n\ncoma, or loss of consciousness, or has had recurrent episodes of hypoglycemia over the past 8 weeks\n\n* has a history of intolerance or hypersensitivity, or has any contraindication to sitagliptin, insulin, or metformin\n* is on a weight loss program and not in the maintenance phase, or has started a weight loss medication or has undergone bariatric surgery within 12 months\n* has undergone a surgical procedure within 4 weeks or has planned major surgery during the study\n* has a medical history of active liver disease\n* has had new or worsening signs or symptoms of coronary heart disease within the past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder\n* has a diagnosis of congestive heart failure with New York Heart Association Class III - IV cardiac status\n* has a systolic blood pressure \u2265 160 mmHg or a diastolic blood pressure \u2265 90 mmHg\n* has human immunodeficiency virus (HIV)\n* has severe peripheral vascular disease\n* is currently being treated for hyperthyroidism or is on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks\n* has a history of malignancy \u2264 5 years before the study, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* has a clinically important hematological disorder (such as aplastic anemia,\n\nmyeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n* is pregnant or breast feeding, or is expecting to conceive or donate eggs during the study, including 14 days after the last dose of study medication\n* is a user of recreational or illicit drugs or has had a recent history of drug abuse", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "27740719", "type": "RESULT", "citation": "Shankar RR, Bao Y, Han P, Hu J, Ma J, Peng Y, Wu F, Xu L, Engel SS, Jia W. Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. J Diabetes Investig. 2017 May;8(3):321-329. doi: 10.1111/jdi.12585. Epub 2016 Dec 9."}], "availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/study.html?id=0431-254&kw=0431-254&tab=access"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "This study was performed with research participants at 28 study centers in China.", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}, {"id": "FG001", "title": "Placebo", "description": "Participants treated with placebo to sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "234"}, {"groupId": "FG001", "numSubjects": "233"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "217"}, {"groupId": "FG001", "numSubjects": "217"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "16"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Other Protocol Specified Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin", "description": "Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}, {"id": "BG001", "title": "Placebo", "description": "Participants treated with placebo to sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "234"}, {"groupId": "BG001", "value": "233"}, {"groupId": "BG002", "value": "467"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.6", "spread": "8.4"}, {"groupId": "BG001", "value": "56.7", "spread": "9.1"}, {"groupId": "BG002", "value": "57.6", "spread": "8.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "104"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "221"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "130"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "246"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin", "populationDescription": "The Full Analysis Set (FAS) consisted of all randomized participants receiving insulin alone or in combination with metformin, took at least one dose of study treatment, had at least one observation for the analysis endpoint subsequent to the first dose of study treatment, and had baseline data for the analysis endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "A1C %", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}, {"id": "OG001", "title": "Placebo", "description": "Participants treated with placebo to sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "223"}, {"groupId": "OG001", "value": "219"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.67", "lowerLimit": "-0.79", "upperLimit": "-0.55"}, {"groupId": "OG001", "value": "-0.32", "lowerLimit": "-0.44", "upperLimit": "-0.20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Robust Regression", "statisticalComment": "Robust regression using M-estimation with terms for treatment and the metformin stratum and type of insulin, and baseline A1C (%) as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.50", "ciUpperLimit": "-0.19"}]}, {"type": "SECONDARY", "title": "Change From Baseline in HbA1C Levels at Week 24 in Participants Receiving Insulin in Combination With Metformin", "populationDescription": "The FAS consisted of all randomized participants receiving insulin in combination with metformin, took at least one dose of study treatment, had at least one observation for the analysis endpoint subsequent to the first dose of study treatment, and had baseline data for the analysis endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "A1C %", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}, {"id": "OG001", "title": "Placebo", "description": "Participants treated with placebo to sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "104"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.72", "lowerLimit": "-0.89", "upperLimit": "-0.55"}, {"groupId": "OG001", "value": "-0.34", "lowerLimit": "-0.51", "upperLimit": "-0.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Robust Regression", "statisticalComment": "Robust regression using M-estimation with terms for treatment and type of insulin, and baseline A1C (%) as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.61", "ciUpperLimit": "-0.14"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin", "populationDescription": "The FAS consisted of all randomized participants receiving insulin alone or in combination with metformin, took at least one dose of study treatment, had at least one observation for the analysis endpoint subsequent to the first dose of study treatment, and had baseline data for the analysis endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}, {"id": "OG001", "title": "Placebo", "description": "Participants treated with placebo to sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "203"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-47.9", "lowerLimit": "-57.0", "upperLimit": "-38.8"}, {"groupId": "OG001", "value": "-21.3", "lowerLimit": "-30.3", "upperLimit": "-12.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with terms for treatment and the metformin stratum and type of insulin, and baseline 2-hr Post- Meal Glucose (mg/dL) as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-26.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-38.4", "ciUpperLimit": "-14.7"}]}, {"type": "PRIMARY", "title": "Number of Participants With One or More Adverse Events", "description": "An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "The All Patients as Treated (APaT) population consisted of all randomized participants who received at least one dose of study treatment. Participants were included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 26", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}, {"id": "OG001", "title": "Placebo", "description": "Participants treated with placebo to sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "234"}, {"groupId": "OG001", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "116"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Discontinuing Study Medication Due to an AE", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "The APaT population consisted of all randomized participants who received at least one dose of study treatment. Participants were included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}, {"id": "OG001", "title": "Placebo", "description": "Participants treated with placebo to sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "234"}, {"groupId": "OG001", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to Week 26", "description": "The APaT population consisted of all randomized patients who received at least one dose of study treatment. Participants were included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.", "seriousNumAffected": 4, "seriousNumAtRisk": 234, "otherNumAffected": 83, "otherNumAtRisk": 234}, {"id": "EG001", "title": "Placebo", "description": "Participants treated with placebo to sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for \u226510 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.", "seriousNumAffected": 9, "seriousNumAtRisk": 233, "otherNumAffected": 68, "otherNumAtRisk": 233}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 233}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 233}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 233}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 233}]}, {"term": "Duodenal ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 233}]}, {"term": "Gastric polyps", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 233}]}, {"term": "Diabetic foot infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 233}]}, {"term": "Lung infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 233}]}, {"term": "Fibula fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 233}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 233}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 233}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 233}]}, {"term": "Vertebrobasilar insufficiency", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 233}]}, {"term": "Diabetic nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 233}]}, {"term": "Renal failure chronic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 233}]}], "otherEvents": [{"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 40, "numAffected": 16, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 32, "numAffected": 13, "numAtRisk": 233}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 12, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 13, "numAffected": 11, "numAtRisk": 233}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 173, "numAffected": 65, "numAtRisk": 234}, {"groupId": "EG001", "numEvents": 150, "numAffected": 52, "numAtRisk": 233}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["China"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M26073", "name": "Insulin, Long-Acting", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}